Rani Therapeutics Holdings, Inc. has announced a research agreement with Chugai Pharmaceutical Co., Ltd. to evaluate the potential of Rani’s oral delivery technology, specifically the RaniPill ...

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2024 Earnings Call Transcript March 31, 2025 Rani Therapeutics Holdings, Inc. misses on earnings expectations. Reported EPS is $-0.27 EPS ...

Rani Therapeutics, LLC - Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 - - Announced topline results from the Phase 1 repeat-dose study of RT-102 for the treatment of ...

Rani Therapeutics shares are trading lower by 23% Tuesday afternoon. The company announced a $10 million direct offering of 3 million shares at $3 per share. Unlock your all-in-one trading ...

HC Wainwright restated their buy rating on shares of Rani Therapeutics (NASDAQ:RANI – Free Report) in a research note released on Thursday,Benzinga reports. HC Wainwright currently has a $9.00 ...

Rani Therapeutics announced positive preclinical data for RT-114 and semaglutide, advancing toward Phase 1 obesity trials in mid-2025. Rani Therapeutics Holdings, Inc. has announced preclinical ...

Rani Therapeutics shares are trading lower by 23% Tuesday afternoon. The company announced a $10 million direct offering of 3 million shares at $3 per share.

March 22, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today reported financial ...

SAN JOSE, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs ...

- Announced positive topline Phase 1 results of RT-102 for the treatment of osteoporosis - - Anticipate initiating an additional Phase 1 clinical trial in 2H 2022 - - Capitalized to fund ...